登录    
  
首页 > 期刊论文 > 论文摘要
CD26/DPPⅣ与肿瘤相关的研究进展
         
Progress in CD26/DPPⅣ and tumor

摘    要
二肽基肽酶Ⅳ(dipeptidyl peptidase Ⅳ,DPPⅣ)也称为CD26,是一种具有多种生物学功能的蛋白酶,参与信号转导和免疫细胞激活等过程,其异常表达和活化与多种疾病的发生和发展密切相关。在某些肿瘤中,随着疾病进展,CD26表达水平降低,提示其是一种肿瘤抑制因子。另一方面,CD26又是与肿瘤侵袭相关的蛋白,参与调节细胞增殖、迁移和黏附等恶性表型及相关病理过程,被认为是恶性肿瘤及肿瘤干细胞的标志物之一。因此,CD26与肿瘤发生、发展及诊断、治疗具有密切联系。本文就近几年来CD26在肿瘤方面的研究进展进行综述,以期为CD26应用于肿瘤临床诊断、治疗和预后评估等提供理论依据。
标    签 肿瘤   二肽基肽酶4   基因表达   肿瘤干细胞   Neoplasms   Dipeptidyl peptidase 4   Gene expression   Neoplastic stem cells  
 
Abstract
Dipeptidyl peptidase Ⅳ (DDPⅣ), also known as CD26, is a protease with a variety of biological functions, which is involved in signal transduction and activation of immune cells. The abnormal expression and activation of CD26 are closely related to the occurrence and development of many diseases. In some tumors, the expression level of CD26 decreases with the disease progression, suggesting that CD26 is a tumor suppressor. On the other hand, CD26 has also been described as a protein related to the invasion of malignant tumor, involved in the regulation of cell malignant phenotypes such as proliferation, migration and adhesion, as well as the related pathological processes, so CD26 is considered to be a marker of malignant tumor and cancer stem cells. Therefore, CD26 is closely associated with the occurrence, development, diagnosis and treatment of tumors. In this article, the research progress in CD26 and the relevant tumors in recent years is reviewed to provide the theoretical basis for the application of CD26 in clinical diagnosis, treatment and prognosis evaluation of tumors.

中图分类号 R711.74   DOI 10.3781/j.issn.1000-7431.2017.55.299

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 综述

基金项目 南通大学博士研究生科技创新计划项目(编号:YKC15003);江苏省青年医学重点人才计划项目(编号:QNRC2016704)

收稿日期 2017/5/17

修改稿日期 2017/6/28

网络出版日期

作者单位点击查看


引用该论文: YANG Xiaoqing,ZHANG Yuquan. Progress in CD26/DPPⅣ and tumor[J]. Tumor, 2017, 37(10): 1112~1118
杨晓清,张玉泉. CD26/DPPⅣ与肿瘤相关的研究进展[J]. 肿瘤, 2017, 37(10): 1112~1118


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide[J]. Histochemie, 1966, 7(3):197-201.
 
【2】Aliyari Serej Z, Ebrahimi Kalan A, Mehdipour A, et al. Regulation and roles of CD26/DDPⅣ in hematopoiesis and diseases[J]. Biomed Pharmacother, 2017, 91:88-94.
 
【3】Yazbeck R, Jaenisch SE, Abbott CA. Potential disease biomarkers:dipeptidyl peptidase 4 and fibroblast activation protein[J/OL]. Protoplasma, 2017(2017-06-06)[2017-08-20]. https://link.springer.com/article/10.1007%2Fs00709-017-1129-5.
 
【4】Baticic PL, Pernjak PE, Detel D, et al. Involvement of DPPⅣ/CD26 in cutaneous wound healing process in mice[J]. Wound Repair Regen, 2017, 25(1):25-40.
 
【5】Beckenkamp A, Davies S, Willig JB, et al. DDPⅣ/CD26:a tumor suppressor or a marker of malignancy?[J]. Tumour Biol, 2016, 37(6):7059-7073.
 
【6】de Andrade CF, Bigni R, Pombo-de-Oliveira MS, et al. CD26/DDPⅣ cell membrane expression and DDPⅣ activity in plasma of patients with acute leukemia[J]. J Enzyme Inhib Med Chem, 2009, 24(3):708-714.
 
【7】Matuszak M, Lewandowski K, Czyż A, et al. The prognostic significance of surface dipeptidyl peptidaseⅣ (CD26) expression in B-cell chronic lymphocytic leukemia[J]. Leuk Res, 2016, 47:166-71.
 
【8】Yamochi T, Yamochi T, Aytac U, et al. Regulation of p38 phosphorylation and topoisomeraseⅡalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidaseⅣ is associated with enhanced in vitro and in vivo sensitivity to doxorubicin[J]. Cancer Research, 2005, 65(5):1973-1983.
 
【9】Broxmeyer HE, Capitano M, Campbell TB, et al. Modulation of hematopoietic chemokine effects in vitro and in vivo by DPP-4/CD26[J]. Stem Cells Dev, 2016, 25(8):575-585.
 
【10】O'Leary HA, Capitano M, Cooper S, et al. DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms[J/OL]. Leukemia, 2017(2017-04-21)[2017-08-21]. https://www.nature.com/leu/journal/vaop/ncurrent/full/leu201798a.html. DOI:10.1038/leu.2017.98.
 
【11】Pang R, Law WL, Chu AC, et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer[J]. Cell Stem Cell, 2010, 6(6):603-615.
 
【12】Cutler MJ, Lowthers EL, Richard CL, et al. Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26[J]. BMC Cancer, 2015, 15:882.
 
【13】Wahab SMR, Islam F, Gopalan V, et al. The identifications and clinical implications of cancer stem cells in colorectal cancer[J]. Clin Colorectal Cancer, 2017, 16(2):93-102.
 
【14】Lieto E, Galizia G, Orditura M, et al. CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence[J]. Oncol Lett, 2015, 9(2):542-550.
 
【15】Nishikawa S, Konno M, Hamabe A, et al. Surgically resected human tumors reveal the biological significance of the gastric cancer stem cell markers CD44 and CD26[J]. Oncol Lett, 2015, 9(5):2361-2367.
 
【16】Jiang YX, Yang SW, Li PA, et al. The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms[J]. Oncogene, 2017, 36(9):1256-1264.
 
【17】Ye C, Tian X, Yue G, et al. Suppression of CD26 inhibits growth and metastasis of pancreatic cancer[J]. Tumour Biol, 2016, 37(12):15677-15686.
 
【18】Busek P, Vanickova Z, Hrabal P, et al. Increased tissue and circulating levels of dipeptidyl peptidase-Ⅳ enzymatic activity in patients with pancreatic ductal adenocarcinoma[J]. Pancreatology, 2016, 16(5):829-838.
 
【19】Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies[J]. Gastroenterology, 2011, 141(1):150-156.
 
【20】Nagel AK, Ahmed-Sarwar N, Werner PM, et al. Dipeptidyl peptidase-4 inhibitor-associated pancreatic carcinoma:a review of the FAERS database[J]. Ann Pharmacother, 2016, 50(1):27-31.
 
【21】Buse JB, Bethel MA, Green JB, et al. Pancreatic safety of sitagliptin in the TECOS study[J]. Diabetes Care, 2017, 40(2):164-170.
 
【22】Liang PI, Yeh BW, Li WM, et al. DPP4/CD26 overexpression in urothelial carcinoma confers an independent prognostic impact and correlates with intrinsic biological aggressiveness[J]. Oncotarget, 2017, 8(2):2995-3008.
 
【23】Inamoto T, Yamochi T, Ohnuma K, et al. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix[J]. Clin Cancer Res, 2006, 12(11 Pt 1):3470-3477.
 
【24】Rathmann W, Kostev K. Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer[J]. J Diabetes Complications, 2017, 31(4):687-692.
 
【25】Lu Z, Qi L, Bo XJ, et al. Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters[J]. J Res Med Sci, 2013, 18(8):647-652.
 
【26】Angevin E, Isambert N, Trillet-Lenoir V, et al. First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers[J]. Br J Cancer, 2017, 116(9):1126-1134.
 
【27】Tilan JU, Lu C, Galli S, et al. Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects[J]. Oncotarget, 2013, 4(12):2487-2501.
 
【28】Tilan JU, Krailo M, Barkauskas DA, et al. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma-associations with tumor phenotype and survival[J]. Cancer, 2015, 121(5):697-707.
 
【29】Barreira da Silva R, Laird ME, Yatim N, et al. Dipeptidyl peptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immuno-therapy[J]. Nat Immunol, 2015, 16(8):850-858.
 
【30】Choi HJ, Kim JY, Lim SC, et al. Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression[J]. Br J Pharmacol, 2015, 172(21):5096-5109.
 
【31】Wolczyk D, Zaremba-Czogalla M, Hryniewicz-Jankowska A, et al. TNF-α promotes breast cancer cell migration and enhances the concentration of membrane-associated proteases in lipid rafts[J]. Cell Oncol (Dordr), 2016, 39(4):353-363.
 
【32】Zhang M, Xu L, Wang X, et al. Expression levels of seprase/FAP alpha and DDPⅣ/CD26 in epithelial ovarian carcinoma[J]. Oncol Lett, 2015, 10(1):34-42.
 
【33】Yang X, Zhang X, Wu R, et al. DDPⅣ promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis[J]. Oncotarget, 2017, 8(5):8679-8692.
 
【34】Miyake Y, Aratake Y, Sakaguchi T, et al. Examination of CD26/DDPⅣ, p53, and PTEN expression in thyroid follicular adenoma[J]. Diagn Cytopathol, 2012, 40(12):1047-1053.
 
【35】Kagdi HH, Demontis MA, Fields PA, et al. Risk stratification of adult T-cell leukemia/lymphoma using immunophenotyping[J]. Cancer Med, 2017, 6(1):298-309.
 
【36】Gibson JF, Huang J, Liu KJ, et al. Cutaneous T-cell lymphoma (CTCL):current practices in blood assessment and the utility of T-cell receptor (TCR)-Ⅴβ chain restriction[J]. J Am Acad Dermatol, 2016, 74(5):870-877.
 
【37】Jang JH, Baerts L, Waumans Y, et al. Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice[J]. Clin Exp Metastasis, 2015, 32(7):677-687.
 
【38】Yang SZ, Ji WH, Mao WM, et al. Elevated levels of preoperative circulating CD44+ lymphocytes and neutrophils predict poor survival for non-small cell lung cancer patients[J]. Clin Chim Acta, 2015, 439:172-177.
 
【39】Blanco-Prieto S, Vazquez-Iglesias L, Rodriguez-Girondo M, et al. Serum calprotectin, CD26 and EGF to establish a panel for the diagnosis of lung cancer[J]. PLoS One, 2015, 10(5):e0127318.
 
【40】Wang H, Liu X, Long M, et al. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis[J]. Sci Transl Med, 2016, 8(334):334ra351.
 
【41】Boccardi V, Marano L, Rossetti RR, et al. Serum CD26 levels in patients with gastric cancer:a novel potential diagnostic marker[J]. BMC Cancer, 2015, 15:703.
 
【42】Varona A, Blanco L, Perez I, et al. Expression and activity profiles of DPPⅣ/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent[J]. BMC Cancer, 2010, 10:193.
 
【43】Sato Y, Kamada T, Yamauchi A. The role of dipeptidyl peptidase 4(DPP4) in the preservation of renal function:DPP4 involvement in hemoglobin expression[J]. J Endocrinol, 2014, 223(2):133-142.
 
【44】Nazarian A, Lawlor K, Yi SS, et al. Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer[J]. Mol Cell Proteomics, 2014, 13(11):3082-3096.
 
【45】Arscott WT, LaBauve AE, May V, et al. Suppression of neuroblastoma growth by dipeptidyl peptidaseⅣ:relevance of chemokine regulation and caspase activation[J]. Oncogene, 2009, 28(4):479-491.
 
【46】Busek P, Stremenova J, Sromova L, et al. Dipeptidyl peptidase-Ⅳ inhibits glioma cell growth independent of its enzymatic activity[J]. Int J Biochem Cell Biol, 2012, 44(5):738-747.
 
【47】Kajiyama H, Shibata K, Ino K, et al. The expression of dipeptidyl peptidaseⅣ (DDPⅣ/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells[J]. Cancer Sci, 2010, 101(2):347-354.
 
【48】Mizokami Y, Kajiyama H, Shibata K, et al. Stromal cell-derived factor-1alpha-induced cell proliferation and its possible regulation by CD26/dipeptidyl peptidaseⅣ in endometrial adenocarcinoma[J]. Int J Cancer, 2004, 110(5):652-659.
 
【49】Zhao W, Mazar J, Lee B, et al. The long noncoding RNA SPRIGHTLY regulates cell proliferation in primary human melanocytes[J]. J Invest Dermatol, 2016, 136(4):819-828.
 
相关信息
   标题 相关频次
 SEPT 9基因与恶性肿瘤关系的研究进展
 4
 Notch2表达与胰腺癌干细胞相关
 4
 靶向miRNA的肿瘤干细胞治疗策略
 4
 大黄素诱导裸鼠体内白血病K562细胞凋亡过程中PI3K/AKT通路相关分子表达的变化
 4
 核干细胞因子与肿瘤的研究进展
 4
 利用GEO公共数据集分析CHAF1A在肿瘤中的表达及临床意义
 4
 缺氧微环境在肿瘤进展中的作用
 4
 晚期糖基化终产物受体异常表达对肿瘤发生和侵袭转移的影响
 4
 乙醛脱氢酶1在人直肠癌中的表达及其预后价值
 4
 肿瘤干细胞标志物CD117在上皮性卵巢癌血管生成拟态中的表达及意义
 4
 肿瘤干细胞与放疗抵抗的研究进展
 4
 肿瘤相关基因STK33生物学特性的研究进展
 4
 G蛋白偶联受体30在子宫内膜癌Ishikawa细胞中的表达及亚细胞定位
 3
 Myc相关微型RNA在肿瘤中的研究进展
 3
 长程多柔比星化疗富集乳腺肿瘤干细胞
 3
 干细胞标志CD90与人肺腺癌A549细胞顺铂耐药之间的关系
 3
 吉非替尼耐药细胞株的筛选和基因谱表达研究
 3
 CDC 25ACDC 25B基因在宫颈癌中的表达和临床意义
 2
 CRISPR/Cas9基因编辑技术在肿瘤研究及治疗中的应用
 2
 E2F-1基因反转录病毒载体的构建及其对人胃癌细胞MGC-803增殖的影响
 2
 EGFL6基因沉默对人黑素瘤细胞增殖及侵袭的影响
 2
 EIF5A2基因在恶性肿瘤中的研究进展
 2
 Gadd45G基因在食管鳞癌组织中的异常甲基化及表达
 2
 HOX11原癌基因的活化对儿童急性白血病预后的影响
 2
 KAI1基因异常表达与甲状腺乳头状癌发生、发展的关系
 2
 MS4A基因家族与肿瘤的研究进展
 2
 PTENsurvivin在宫颈腺癌中的表达及其与HPV16/18感染的关系
 2
 S100A4基因差异表达与结直肠癌分化、转移及预后的关系
 2
 survivin mRNA及蛋白在肺癌组织芯片中的表达及意义
 2
 Survivin反义寡核苷酸对卵巢癌细胞株凋亡和侵袭、迁移的影响
 2

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2